Key result
A two-dose booster regimen of conventional inactivated polio vaccine achieved 100% seropositivity against all tested wild, virulent, and vaccine-derived poliovirus strains in Japanese adults.
Why the study?
Booster vaccination is recommended for Japanese travelers to polio-endemic or high-risk countries, but the immunogenicity of a two-dose conventional inactivated polio vaccine booster regimen needed evaluation.
Does a two-dose booster of conventional inactivated polio vaccine improve immunogenicity against poliovirus strains in healthy Japanese adults?
Observational (n=61)
No
Does a two-dose booster of conventional inactivated polio vaccine improve immunogenicity against poliovirus strains in healthy Japanese adults?
A two-dose booster regimen of conventional inactivated polio vaccine is safe and highly immunogenic in Japanese adults previously immunized with oral polio vaccine.
Answers are grounded in this paper and cite their sources.
May inform adult IPV booster strategies; leaves open durability and generalizability in RCTs.
Background: Most Japanese adults have been vaccinated twice in childhood with the Sabin oral polio vaccine as part of routine immunization schedules. Booster vaccination is recommended for Japanese travelers to polio-endemic or high-risk countries. This study assessed the immunogenicity of a two-dose booster regimen of conventional inactivated polio vaccine (cIPV) in Japanese adults.Methods: Healthy Japanese adults aged 20 years or older received two doses of standalone cIPV derived from virulent strains (Imovax Polio®). Serum samples were obtained before the booster vaccination and 4–6 weeks after each vaccination. Immunogenicity was evaluated by measuring serum neutralization titers against type 1, 2, and 3 poliovirus strains using a microneutralization assay. Results: The subjects were 61 healthy Japanese adults (26 men and 35 women) with mean ± standard deviation age of 35.8 ± 8.0 years. The seropositivity rates (i.e., percentage of subjects with anti-polio antibody titers ≥1:8 ) before booster vaccination were 88.5%, 95.1%, and 52.5% for Sabin strains (type 1, 2, and 3, respectively); 72.1%, 93.4%, and 31.1% for virulent poliovirus strains (type1: Mahoney strain; type 2: MEF-1 strain; and type 3: Saukett strain, respectively); and 93.4%, 93.4%, 93.4% and 88.5% for type 2 vaccine-derived poliovirus strains (SV3128, SV3130, 11196, and 11198, respectively). After one dose of cIPV, all seropositivity rates increased to 98.4%–100.0%. After two doses of cIPV, seropositivity rates reached 100% for all strains. cIPV was well tolerated, with no safety concerns. Conclusion: Booster vaccination with standalone cIPV induced a robust immune response in Japanese adults. Trial registration: UMIN, UMIN000013551. Registered 28 March 2014 - Retrospectively registered, https://upload.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000015830
No takes yet. Share an insight, caveat, or question.
Fukushima et al. (2020) conducted an observational in Healthy adults requiring polio booster (n=61). Conventional inactivated polio vaccine (cIPV) was evaluated on Seropositivity rates (neutralization titers ≥ 1:8) against poliovirus strains. A two-dose booster regimen of conventional inactivated polio vaccine achieved 100% seropositivity against all tested wild, virulent, and vaccine-derived poliovirus strains in Japanese adults.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: